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Newcastle University, Newcastle upon Tyne, UKRetinitis pigmentosa (RP) is the most common form of in-
herited vision loss and is characterized by degeneration of
retinal photoreceptor cells and the retinal pigment epithelium
(RPE). Mutations in pre-mRNA processing factor 31 (PRPF31)
cause dominant RP via haploinsufficiency with incomplete
penetrance. There is good evidence that the diverse severity
of this disease is a result of differing levels of expression of
the wild-type allele among patients. Thus, we hypothesize
that PRPF31-related RP will be amenable to treatment by ad-
eno-associated virus (AAV)-mediated gene augmentation ther-
apy. To test this hypothesis, we used induced pluripotent stem
cells (iPSCs) with mutations in PRPF31 and differentiated
them into RPE cells. The mutant PRPF31 iPSC-RPE cells reca-
pitulate the cellular phenotype associated with the PRPF31 pa-
thology, including defective cell structure, diminished phago-
cytic function, defects in ciliogenesis, and compromised
barrier function. Treatment of the mutant PRPF31 iPSC-RPE
cells with AAV-PRPF31 restored normal phagocytosis and cilia
formation, and it partially restored structure and barrier func-
tion. These results suggest that AAV-based gene therapy target-
ing RPE cells holds therapeutic promise for patients with
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With a prevalence rate of approximately 1 in 3,500, retinitis pigmen-
tosa (RP) is the most common form of inherited blindness, and it can
be inherited in autosomal dominant, autosomal recessive, or X-linked
patterns.1 The general pathology of RP is degeneration of the retinal
pigment epithelium (RPE) and photoreceptor cells, sometimes lead-
ing to complete vision loss.2 The most common causes of autosomal
dominant RP are mutations in rhodopsin, followed by mutations in
precursor mRNA (pre-mRNA) processing factors PRPF3, PRPF4,
PRPF6, PRPF8, PRPF31, and SNRNP200.3–7 Among these, mutations
in PRPF31 are the most common and are estimated to account for
approximately 10% of dominant RP.8 PRPF31 encodes a ubiquitously
expressed splicing factor, which binds and stabilizes the tri-small nu-
clear ribonucleoprotein particle (snRNP) U4/U6-U5 ribonucleopro-
tein complex.9–11 It remains unclear why mutations in ubiquitously392 Molecular Therapy: Methods & Clinical Development Vol. 15 Decem
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Data obtained from studies of PRPF31-associated disease suggest
that alterations in RNA splicing underlie these forms of inherited
retinal degeneration (IRD).12
RP frommutations in PRPF31 stems from nonsense mutations, large-
scale deletions, and premature stop codons affecting one allele.10
These mutations create null alleles and cause disease via haploinsuf-
ficiency. Complete loss of PRPF31 function results in embryonic
lethality.10 Since mutations in PRPF31 cause disease via haploinsuffi-
ciency, it is a dominant disease that is a good candidate for treatment
via gene augmentation therapy. Furthermore, evidence from studies
of the reduced penetrance of disease observed in some families with
PRPF31-associated retinal degeneration shows that increased expres-
sion of PRPF31 from the wild-type allele can reduce disease
severity.13–15 For gene-based therapies, adeno-associated virus
(AAV) vectors are at the forefront, since they are known to be non-
pathogenic while simultaneously staying successful at penetrating
cell membranes and mostly evading the immune system.16 Last
year, the first US Food and Drug Administration (FDA)-approved
gene therapy treatment for inherited retinal diseases was successfully
performed in patients with mutations in the RPE-specific 65-kDa
protein (RPE65) gene. Sub-retinal injection of the RPE65-expressing
AAV vector restores normal function of this protein and leads to
vision improvement.17 Stimulated by this initial success, clinical trials
of AAV-mediated gene augmentation therapies are in progress for
multiple genetic subtypes of IRD.18–23
Among other functions, the RPE nourishes photoreceptor cells and
phagocytoses shed photoreceptor outer segments (POSs).24 Muta-
tions in PRPF31 primarily led to RPE degeneration in cellular andber 2019 ª 2019 The Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CRISPR-Edited iPSC PRPF31+/–
(A) Schematic representation of the PRPF31 locus. A 20-
bp nucleotide gRNA sequence (blue line) is followed by
PAM (red line) designed to target exon 7. Bottom
sequence shows the 10-bp deletion found in clone no.
144, which was used for differentiation into RPE. (B)
mRNA levels of PRPF31 normalized to GAPDHmeasured
in triplicate, expressed by CRISPR-edited iPSC
PRPF31+/+ (wild-type [WT]) clones 156 and 157, and
PRPF31+/ (heterozygous [HET]) mutant clones 118 (4-bp
deletion) and 144 (10-bp deletion). The average expres-
sion of WT cells was used as a value of 1 for relative
quantification (two-way ANOVA, ****p < 0.0001; data are
represented as mean ± SD).
www.moleculartherapy.orgmouse models of PRPF31-linked RP.9,12,25 Specifically, RPE cells from
Prpf31 mutant mice show progressive degeneration and a cell-auton-
omous phagocytic defect associated with decreased binding and inter-
nalization of POSs that eventually leads to photoreceptor loss.6
Since RPE can be derived from induced pluripotent stem cells
(iPSCs), the RPE pathology associated with mutations in PRPF31
can be modeled using patient derived iPSC-RPE. Indeed, iPSC-RPE
generated from patients with PRPF31-associated retinal degeneration
show decreased phagocytosis and abnormal cilia growth.12 In the
studies reported here, we used one of these patient-derived iPSC lines
and a newly generated PRPF31+/ iPSC cell line to test the use of
AAV-mediated gene augmentation therapy to treat PRPF31-associ-
ated retinal degeneration. Data obtained from these studies support
the use of AAV-mediated gene augmentation therapy to treat
PRPF31-associated disease.
RESULTS
Generation of iPSC-RPE Cells PRPF31+/– via CRISPR-Cas9
Editing
To test AAV-mediated gene augmentation therapy for PRPF31-associ-
ated IRD, we used iPSC-derived RPE cells from two sources. The first
source is iPSC-derived RPE cells from a patient with an 11-bp deletion
in exon 11 of PRPF31, causing RP.12 RPE cells derived from the same
iPSC line in which the 11-bp deletion was corrected were used as con-
trols.12 These PRPF31 mutant iPSC-derived RPE cells reproduce
in vitro key features associated with PRPF31 pathology, such as defec-
tive splicing, decreased phagocytosis, and shorter cilia.12 The second
source of iPSCs is wild-type IMR90 iPSCs into which we introduced
a null allele of PRPF31 using CRISPR/Cas9-mediated genome editing.
To accomplish this modification, we transfected wild-type iPSCs with
the pSpCas9(BB)2A-EGFP (PX458) plasmid carrying the Cas9
nuclease and a guide RNA (gRNA) targeting exon 7 of PRPF31 (Fig-
ure 1). EGFP-positive cells were sorted and expanded to generate clonal
cell lines. Screening of the clones via PCR and sequencing identified 18/
255 clones with mutations in PRPF31 (8%). The most common indels
found in these clones were 4-bp and 10-bp deletions in exon 7 of
PRPF31, which resulted in frameshift mutations, causing premature
stop codons in exons 7 and 8, respectively (Figure 1). Cells transfected
with editing reagents, but that did not have a mutation in PRPF31, were
expanded for use as controls. In clones harboring both the 4-bp andMolecular The10-bp deletions, the mRNA levels of PRPF31 were reduced to half
compared to counterpart wild-type clones (Figure 1B; two-way
ANOVA, p < 0.0001).
One wild-type clone (clone no. 157) and one clone harboring the 10-
bp deletion in one allele of PRPF31 (clone no. 144) were chosen
for further differentiation into RPE cells, according to a previously
established protocol.26,27 At passage 2 (p2), iPSC-RPE cells on trans-
wells displayed typical honeycomb morphology, pigmentation, and
polarization (Figure 2). The RPE monolayer was formed as shown
by the expression of the tight-junction protein ZO-1 (Figures 2C
and 2D). Successful differentiation into RPE cells was determined
through expression of the RPE markers RPE65, TYR (pigmentation
enzyme), and RLBP1 (a visual cycle gene), which were not expressed
in the iPSCs (Figure 2E). To be functional, the RPE monolayer needs
to be highly polarized.24 One of the methods to assay RPE polariza-
tion is measuring the transepithelial electrical resistance (TER).
Despite the normal expression of ZO-1, the engineered iPSC-RPE
PRPF31+/ cells showed significantly lower TER than did the coun-
terpart wild-type cells (t test, n = 4/genotype; p = 0.0009), corrobo-
rating results found in patient-derived iPSC-RPE cells (Figure 2F).12
To test phagocytosis function of the PRPF31+/ iPSC-RPE, CRISPR-
edited PRPF31+/+ and PRPF31+/ iPSC-RPE cells were incubated
with POSs for 30 min, 2 h, and 5 h. Analyses showed significant
defects in both POS binding (two-way ANOVA, p = 0.0001) and
internalization (two-way ANOVA, p = 0.0027) of POSs in
PRPF31+/ cells compared to wild-type cells at 2 h (Figures 2G and
2H). Differences in binding and internalization were not significant
at 30 min and 5 h (Figures 2G and 2H). The first time point is too
short and did not allow enough time for the POSs to bind the cells,
while at 5 h of incubation both wild-type and mutant cells are satu-
rated with POSs.
Optimization of AAV Vectors to Be Used for Gene Therapy in
iPSC-RPE Cells
Since PRPF31-associated retinal degeneration results from haploin-
sufficiency, AAV-mediated gene augmentation therapy can theoreti-
cally be used to rescue the retinal degeneration phenotype. Using
mature iPSC-RPE at p2 on transwells, we tested a panel of AAVrapy: Methods & Clinical Development Vol. 15 December 2019 393
Figure 2. Characterization of the CRISPR-Edited iPSC-RPE Cell Monolayer
(A and B) Brightfield micrograph of mature iPSC-RPE PRPF31+/+ (A) and PRPF31+/ (B) cells on transwells. (C and D) Fluorescent micrographs of mature CRISPR-edited
iPSC-RPE PRPF31+/+ (C) and PRPF31+/ (D) cells grown on transwells and immunostained with anti-ZO-1 antibody (red) and DAPI (blue). (E) RPE markers normalized to
UBE2R2 expressed by mature iPSC-RPE cells wild-type PRPF31+/+ (+/+ black bars) and mutant PRPF31+/ (+/ gray bars) compared to iPSCs (white bars, no expression
found) (n = 3 replicates/cell type; data are represented as mean ± SD). (F) Transepithelial electrical resistance (TER) of mature iPSC-RPE cells on transwells (four replicates/
genotype; two-way ANOVA, ***p < 0.001; data are represented as mean ± SD). (G and H) Quantification of FITC-labeled POSs (G) bound and (H) internalized by CRISPR-
edited iPSC-RPE PRPF31+/+ and PRPF31+/ cells at 30 min, 2 h, and 5 h (two-way ANOVA, **p < 0.01, ****p < 0.0001; data are represented as mean ± SD).
Molecular Therapy: Methods & Clinical Developmentwith a variety of serotypes (AAV2/2, AAV2/5, and AAV2/Anc80) ex-
pressing EGFP under the control of two different promoters: the reg-
ular cytomegalovirus (CMV), and the synthetic CASI promoter,
which contains a portion of CMV, a portion of the chicken b-actin
promoter, and a portion of the UBC enhancer.28 In addition, different
MOIs by AAV were tested at 25,000, 50,000 or 100,000 viral genome
copies per cell (GC/cell). To determine the highest transduction
efficiency and stability, EGFP-positive cells were counted at time
points 72 h, 2 weeks, 4 weeks, and 8 weeks post-transduction using
fluorescence-activated cell sorting (FACS) (Figure 3). At 72 h post-
transduction, cell toxicity was highest when transduced with the
AAV2/5 serotype (two-way ANOVA, n = 2 replicates/condition;
p < 0.0001). Toxicity for each AAV tested was increased at the higher
titer, except for cells transduced with AAV2/Anc80, which did not
show significant differences between 25,000 and 100,000 GC/cell
(Figure 3A). AAV 2/2 and AAV2/Anc80 serotypes showed similar
levels of long-term transduction, with the CASI promoter expressing
higher levels of GFP versus CMV (two-way ANOVA, n = 2 replicates/
condition; p < 0.0001) (Figure 3B). For the construct expressing
the PRPF31 gene, we chose the serotype AAV2/Anc80 with the
CASI promoter, due to the lower cell toxicity at a higher titer, higher
transduction expression of GFP, and high reported in vivo transduc-
tion efficiency.29,30 A detailed AAV-PRPF31 vector map is provided
in Figure S1.
Functional Defects inMutant iPSC-RPEPRPF31+/–Cells CanBe
Rescued with AAV-Mediated Gene Augmentation
Phagocytic Defects in iPSC-RPE PRPF31+/– Can Be Rescued by
AAV-Mediated Gene Augmentation
To test the use of gene augmentation therapy for PRPF31-associ-
ated disease, we treated patient-derived and CRISPR-edited394 Molecular Therapy: Methods & Clinical Development Vol. 15 DecemiPSC-RPE PRPF31+/ cells and control cells with AAV-
PRPF31.12 For these studies, differentiated iPSC-RPE cells at p2
were plated on Matrigel-coated transwells and cultured in X-
VIVO 10 medium.27 After 4 weeks, cells were confluent and pig-
mented and were transduced with several doses of AAV2/
Anc80 AAP.CASI.V5.PRPF31-mCHERRY.RBG (from now, AAV-
PRPF31). Cells were cultured for an additional 4 weeks after
AAV-PRPF31 treatment, and then PRPF31 expression and phago-
cytosis activity were evaluated. Transduced cells showed stable but
weak expression of mCherry after fixation. Since mCherry is a
C-terminal tag, the autocleavage rate is high and is detected in
both nucleus and cytoplasm (Figure S2). Immunostaining with
antibodies for the V5 N-terminal tag demonstrated stable trans-
duction after 4 weeks and correct localization of the AAV-derived
PRPF31 protein in the nucleus (Figure 3C).
To quantify the expression of AAV-derived PRPF31 versus endoge-
nous PRPF31 by iPSC-RPE cells after treatment, mRNA levels were
measured by qPCR and normalized to GAPDH. As shown in Fig-
ure 3D, endogenous mRNA levels of PRPF31 were reduced to half
in iPSC-RPE PRPF31+/ cells compared to wild-type cells. After treat-
ment, AAV-derived PRPF31 expression increased 4- to 5-fold
compared to endogenous PRPF31 in both PRPF31+/+ and PRPF31+/
 cells. No toxicity effects or morphological changes were observed
in wild-type cells after treatment with AAV.
The phagocytic function of the AAV-PRPF31-treated cells was as-
sayed by challenging the cells with bovine fluorescein isothiocyanate
(FITC)-labeled POSs for 2 h. Treatment with AAV-PRPF31 resulted
in rescue of binding and internalization efficiencies in iPSC-RPE
PRPF31+/ cells (two-way ANOVA, p = 0.0322) (Figure 4).ber 2019
Figure 3. Optimization of AAV Vectors
(A) Percentage of live cells (black bars) and GFP-positive
cells (green bars) 72 h post-transduction with AAV
measured by FACS (mean ± SEM). (B) Percentage of
GFP-positive cells over the total population at 2, 4, and
8 weeks post-transduction with 25,000/cell (25K) AAV
shows stable expression of GFP in iPSC-RPE cells over
time. (C) RPE p2 transduced with 50,000 GC/cell (50K)
AAV-PRPF31 and immunostained with anti-V5 (red) at
4 weeks post-transduction. AAV-derived PRPF31 WT
protein localizes in the nuclei (blue) of the RPE cells.
Scale bars, 50 mm. (D) mRNA levels of PRPF31 in iPSC-
RPE PRPF31+/+ and PRPF31+/ cells before and after
transduction with 50,000 (50K) GC/cell AAV. mRNA
levels of PRPF31 normalized to GAPDH measured in
triplicate are shown (n = 3 replicates/type; data are rep-
resented as mean ± SD; two-way ANOVA, *p < 0.05,
****p < 0.0001).
www.moleculartherapy.orgInterestingly, the phagocytic activity was enhanced in wild-type iPSC-
RPE PRPF31+/+ cells treated with AAV-PRPF31 (Figure 4). Specif-
ically, the capacity of binding POSs increased by 2-fold when the cells
were treated with 100,000 GC/cell (two-way ANOVA, p = 0.0293)
(Figure 4B), while the amount of internalized POSs remained similar
before and after AAV treatment (Figure 4C).
The effect of AAV-PRPF31 treatment on phagocytosis function was
also evaluated in patient-derived iPSC-RPE PRPF31+/ cells and cor-
rected counterparts. The results of these studies demonstrated that
phagocytic activity was also restored in iPSC-RPE PRPF31+/ cells
from a different genetic background in a dose-dependent manner
(Figure 5).
Defects in Cilia Growth in iPSC-RPE PRPF31+/– Can Be Rescued
by AAV-Mediated Gene Augmentation
Among other defects, decreased cilia length was observed in patient-
derived PRPF31+/ iPSC-RPE cells.12 Immunostaining with anti-
bodies for the cilia-specific marker ARL13B showed similar results
in CRISPR-edited iPSC-RPE PRPF31+/ cells grown on transwells
for 8 weeks, compared to wild-type cells (Figure 6). To test the ability
of gene augmentation to correct this cilia defect, patient-derived and
CRISPR-edited iPSC-RPE PRPF31+/ cells were treated with AAV-
PRPF31. Four weeks post-transduction with AAV-PRPF31, cilia
length and incidence were restored to normal in both the patient-
derived and CRISPR-edited iPSC-RPE PRPF31+/ cells (Figure 6)
(two-way ANOVA, n = 50 cells/culture; p < 0.0001). No effect was
observed in wild-type cells treated with the AAV-PRPF31 (Figure 6).
Reduced Barrier Function in iPSC-RPE PRPF31+/– Cultures Is
Partially Rescued by AAV-PRPF31
The barrier function of the iPSC-RPE PRPF31+/ cell monolayer was
compromised, as indicated by lower levels of TER (Figure 2). To
investigate the basis for this, we stained control and PRPF31+/Molecular Themutant iPSC-RPE with antibodies to collagen IV (COL IV) and VI
(COL VI) to assess the polarity of the RPE monolayer and extracel-
lular matrix elaboration. As shown in Figure 7, while the PRPF31+/
 cells remain polarized and expressed COL IV on the basal mem-
brane, the expression pattern was irregular, which indicates disrup-
tion of the basal lamina (Figures 7A and 7B). The basolateral secretion
of COL VI was reduced in the mutant cells compared to wild-type
cells, which denotes insufficient secretion of extracellular matrix
by mutant cells (Figures 7D and 7E). Treatment of the iPSC-RPE
PRPF31+/ cells with AAV-PRPF31 improved the expression pattern
of COL IV and restored normal levels of COL VI production (Figures
7A–7C).
Scanning electron microscopy images revealed the presence of flatter
and harder-to-distinguish cells in PRPF31+/ cultures. The definition
of the cells is partially restored following AAV treatment (Figures
7G–7I). At higher magnification, PRPF31+/ cells displayed fewer
microvilli than controls with peculiarly coiled and flattened structure,
which are also partially restored after treatment with AAV-PRPF31
(Figures 7J–7L).
Disruption of the RPE monolayer in PRPF31+/ cultures was
confirmed by transmission electron microscopy (TEM), in which
cross-section images showed gaps between adjacent cells at the basal
side while apical tight junctions stayed intact (Figures 7M and 7N),
explaining the normal pattern of ZO-1 exhibited by iPSC-RPE
mutant cells (Figure 2). Additionally, stress vacuoles and shorter
microvilli were observed in the mutant iPSC-PRPF31+/ cells. Treat-
ment with AAV-PRPF31 results in fewer stress vacuoles and reduced
gaps between the RPE cells (Figure 7O). Despite improved RPE cell
morphology, TER values were not restored in iPSC-PRPF31+/ cul-
tures after gene therapy treatment (Figure S2), possibly because basal
gaps between cells, although smaller, were still present after treatment
(Figure 7O).rapy: Methods & Clinical Development Vol. 15 December 2019 395
Figure 4. Phagocytosis Defect Is Rescued by AAV-PRPF31
(A–C) Representative confocal fluorescent images (20 objective) and quantification (A) of POSs bound (B) and internalized (C) at 2 h show a significant phagocytosis defect
in PRPF31 mutant cells PRPF31+/ (white bars) compared to wild-type PRPF31+/+ (gray bars). Phagocytic function is restored in mutant cells after gene therapy with
AAV-PRPF31. AAV 50K, 50,000 GC/cell; AAV 100K, 100,000 GC/cell. (n = 2 replicates, 3 fields/replicate; data are represented as mean ± SEM; two-way ANOVA, *p < 0.05,
***p < 0.001).
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Autosomal dominant RP due to mutations in the PRPF31 gene is
caused by haploinsufficiency,10,25 providing an opportunity for treat-
ment with gene-augmentation therapy. In this study, we modeled the
cellular phenotype of the disease to test AAV-based PRPF31 gene
augmentation therapy. Mutant iPSC-RPE PRPF31+/ cells grown
on transwells for 8 weeks recapitulated the cellular phenotype associ-
ated with mutations in PRPF31, including abnormal structure,
decreased phagocytic activity, defective ciliogenesis, and compro-
mised barrier function. AAV-mediated PRPF31 gene augmentation
therapy restored normal phagocytosis function and cilia length and
partially restored barrier function in patient-derived and genome-edi-
ted iPSC-RPE PRPF31+/ cells. To the best of our knowledge, this is
the first proof of concept that AAV-based gene therapy has the poten-
tial to be used for treatment of PRPF31-associated RP.
The RPE monolayer is the primary cell type affected in PRPF31-
related RP, and a number of cell and animal models have been devel-
oped that recapitulate the PRPF31-associated cellular pheno-
types.6,9,12,25,31–33 Consistent with prior reports, both the patient-
derived and genome-edited PRPF31 mutant iPSC-RPE cells used in
the current study demonstrated defective phagocytosis and cilia for-
mation.12 Our data suggest that mutations in PRPF31 affect both
binding and internalization of POSs, with a larger impact in POS
binding, analogous to the defect described in mutant mouse RPE
Prpf31+/ cells.6 Phagocytosis is a critical support function in contin-
uously renewing light-sensitive outer segment portions, which is
necessary for vision.34 With diminished phagocytic activity, individ-
ual POS components are not degraded or recycled back to photore-
ceptors, eventually leading to photoreceptor loss.35
As expected by observations in RPE and optic cups derived from pa-
tients with mutations in PRPF31,12 iPSC-RPE PRPF31+/ cells dis-
played shorter cilia. The cilium is critical for the RPE cell development396 Molecular Therapy: Methods & Clinical Development Vol. 15 Decemand maturation, and for correct polarization of the RPE monolayer,
which supports the photoreceptor integrity.36 Defects in the cilia of
RPE PRPF31+/ cells implies defects in maturation and polarization
that compromise the function of the monolayer. A recent paper using
ciliopathy patient-derived iPSC-RPE cells established the maturation
of the RPE cilium as the primary cause for disease.36 Interestingly, the
authors demonstrated that treatment with modulators of ciliogenesis
can rescue the phagocytosis activity by the RPE cells.36 Based on those
results, we think that the decreased phagocytosis activity observed
in mutant iPSC-RPE PRPF31+/ cells may be secondary to the
abnormal maturation of cilia and microvilli. In any case, the degener-
ation of the RPE occurs first, later leading to degeneration of the
neural retina observed in patients.3,36 Thus, we postulate that the
RPE is the best candidate tissue to be targeted by gene therapy.
In vivo, RPE microvilli interdigitate with photoreceptors, providing
mechanical support and executing the diurnal phagocytic removal
of shed POSs. Although degeneration in mutant mice is slow and
photoreceptors do not show a phenotype associated with Prpf31
defect, mutations in this gene result in diminished adhesion between
RPE microvilli and POSs, which delayed the phagocytic burst after
light onset.6 Our cell-based model has allowed a better characteriza-
tion of the microvilli structure in PRPF31 mutant cells, showing
deficiencies in microvilli length and frequency, as well as a coiled
morphology, which may reduce POS binding to the integrin recep-
tors, thus delaying phagocytic function. Additional structural defects
displayed by the iPSC-RPE PRPF31+/ cells were stress vacuoles and
widened spaces between adjacent cells, which could be a consequence
of high apoptotic rates derived from aberrations in gene splicing.
Splicing defects due to mutations in PRPF31 have been specifically
associated with functional and ultrastructural defects in the RPE.12
For instance, gaps between mutant cells could indicate reduced
expression of focal adhesion genes, whereas diminished collagen
may be associated with changes in regulators of extracellular matrixber 2019
Figure 5. Patient-Derived iPSC-RPE PRPF31+/– Cells Show Dose-Dependent Rescued Phagocytic Function after Treatment with AAV-PRPF31
(A–D) Confocal fluorescent images show FITC-labeled POSs engulfed by the patient-derived iPSC-RPE p2 cells (corrected or mutant for PRPF31) on transwells treated
with (A and B) no AAV, (C) 25,000 GC/cell AAV, or (D) 50,000 GC/cell AAV. Scale bars, 25 mm. (E) Fluorescence was quantified with ImageJ (n = 2/treatment; one-way
ANOVA, p = 0.0655).
www.moleculartherapy.orggenes derived from mutations in PRPF31.12 Further transcriptome
analyses are required to unravel the mechanisms underlying func-
tional and structural defects in the RPE.
Patients with autosomal recessive IRD associated with mutations in
RPE65 have been successfully treated and show improved visual func-
tion after sub-retinal injections with AAV-expressing wild-type
RPE65.17 Furthermore, successful pre-clinical studies and clinical tri-
als of gene therapies for other inherited retinal disorders are in prog-
ress.18–21 Likewise, we think that the visual function in patients with
RP caused by PRPF31 haploinsufficiency can be improved with AAV-
mediated gene augmentation therapy. Based on this premise, we opti-
mized an AAV vector that expresses wild-type PRPF31 under the
CASI promoter, which showed no toxicity in RPE cells. Although
our experiments were performed in vitro, it is hoped the development
of this therapy can be advanced so that it can be used clinically. To
support this goal, the AAV vector used for these studies was generated
with the Anc80 serotype, in which modifications in the viral capsid
makes it more potent to transduce retinal tissue in vivo, as proven
in mice and non-human primate studies.29,30
The results presented here are a proof of concept that AAV-mediated
PRPF31 expression can restore the phagocytic function and the cilia
length of mutant RPE PRPF31+/ cells. Additionally, AAV-PRPF31
partially rescues the barrier function of the iPSC-RPE PRPF31+/
cell monolayer, which displays tighter cell junctions and healthier
RPE cells after treatment. Interestingly, AAV-mediated PRPF31
expression also enhances phagocytic activity in wild-type RPE cells.
Since AAV-based therapy is applied to pre-mature cells, this effect
could imply an accelerated functional maturation of the RPE. Tran-
scriptome analyses of these cells will contribute to understanding
the mechanisms of RPE pathology in patients with PRPF31-linked RP.
It is also important to highlight that AAV-PRPF31 transduced the
RPE cells with high efficiency, increasing 4- to 5-fold the endogenous
levels of PRPF31 without any signs of toxicity, which supports its po-
tential as a therapy for humans. However, based on the FACS ana-
lyses, there is a percentage of cells not targeted by the AAV, which
will likely undergo apoptosis and prevent the TER values from beingMolecular Thecompletely restored. These findings indicate that AAV-based gene
therapy treatment may rescue the function of the RPE cells individu-
ally, while the global function of the RPE monolayer requires that
most cells are targeted by the AAV. Further analyses are required
to investigate whether earlier intervention with the AAV-PRPF31
vector may result in a total rescue of the RPE barrier function. Still,
the rescue provided by AAV-derived PRPF31 may be limited to
certain RPE functions, while others like the barrier function cannot
be rescued. Nonetheless, partial restoration of the RPE function and
structure may be enough to preserve vision in patients with
PRPF31-linked RP. However, the PRPF31 pathology is complex in
patients and has an impact on photoreceptor cells as well, which
makes them additional potential targets for future gene therapy
studies. Supplementary studies in vivo and using iPSC-derived optic
cups may be warranted to identify the right dosage and cellular tar-
gets, as well as the safety of this treatment for human therapy.
MATERIALS AND METHODS
Ethical Considerations
Patient-derived samples used were obtained by Dr. Majlinda Lako’s
laboratory, with informed consent according to the protocols
approved by Yorkshire and the Humber Research Ethics Committee
(REC ref. no. 03/362). Further information on the patients and con-
trols is provided in Buskin et al.12
Culture of iPSCs
IMR90 human iPSCs (hiPSCs) were purchased fromWiCell (Madison,
WI, USA) and cultured on growth factor-reduced (GFR)Matrigel base-
mentmembranematrix (354230, Corning, Bedford, MA, USA)-coated
plates in mTeSR1 (85850, STEMCELL Technologies, Cambridge, MA,
USA). Patient-derived hiPSCs with a 1-bp deletion in PRPF31 and
duplicate cells containing a CRISPR-Cas9 correction were generated
in Dr. Majlinda Lako’s laboratory (Institute of GeneticMedicine, New-
castle University)12,37–40 and cultured similarly to IMR90 hiPSCs.
gRNA Design and CRISPR/Cas9 Genome Editing
The single guide RNA (sgRNA) target sequence (50-GCACCGCATC
TACGAGTATG-30) was generated using the tool http://www.e-crisp.
org/E-CRISP/designcrispr.html, with a score of 91. The sgRNA wasrapy: Methods & Clinical Development Vol. 15 December 2019 397
Figure 6. Shorter Cilia Length in iPSC-RPE PRPF31+/– Cells Is Rescued by AAV-PRPF31
(A–H) Immunostaining for ARL13B shows shorter cilia in both patient-derived and CRISPR-edited iPSC-RPE PRPF31+/ cells compared to wild-type cells. The length of the
cilia is restored after transduction with 50,000 GC/cell of AAV-PRPF31. Due to the physical distance with the cilia, nuclei are out of plane in some of the images. Immu-
nostaining controls with secondary but no primary antibodies are shown in (A) and (E). Scale bars, 25 mm. (I and J) Cilia length measured with ImageJ demonstrates
significantly shorter cilia in PRPF31+/ cells, which is rescued with AAV-based gene therapy (n = 50 cells/culture) (data are represented as mean ± SD; individual cell
measurement values are shown as boxes [wild-type] or circles [PRPF31+/]; two-way ANOVA, ****p < 0.0001).
Molecular Therapy: Methods & Clinical Developmentcloned into the vector pSpCas9(BB)-2A-GFP (PX458) (a gift from
Feng Zhang, Addgene plasmid no. 48138).
Transfection of CRISPR-Edited IMR90 iPSCs
Cells were transfected using the Amaxa Nucleofector Kit V (Lonza,
Morristown, NJ, USA) per the manufacturer’s instructions. Four mi-
crograms of plasmid DNA was transfected per 10 million cells in a
GFR-Matrigel-coated 10-cm dish. Cells were incubated undisturbed
for 48 h in mTeSR1 with 1 mM selective ROCK inhibitor (Y27632,
Tocris, Minneapolis, MN, USA) to increase cell survival rate. After
48 h, positively transfected cells were separated via FACS, due to tran-
sient GFP expression from the vector pSpCas9(BB)-2A-GFP
(PX458). Positive clones were plated on GFR-Matrigel-coated 10-
cm dishes in media composed of 50% fresh mTESR1 and 50% filtered
conditioned media from confluent iPSC cultures until small colonies
formed (roughly 8 days later). To prevent cross-contamination be-
tween clones, colonies were manually dissected and transferred to
one colony per well in 96-well plates and expanded until 60%–70%
confluent (roughly 8 days later). Once split, three replica plates
were created: one to keep cells growing in an incubator, one to analyze
the genotype, and one to freeze clones.41
Recent studies have raised the concern that Cas9 produces a p53-
mediated DNA damage response in iPSCs, which reduces the editing
efficiency.42,43 This finding suggests that defects in p53 improve
the efficiency of genome editing in iPSCs, potentially leading to
the generation of a biased cell population with defective p53.43 To
determine whether this occurred during editing of PRPF31, PBS
only, or 1 mg total of the p53 antagonist MDM2 (E3-204-050,398 Molecular Therapy: Methods & Clinical Development Vol. 15 DecemR&D Systems, Minneapolis, MN, USA) in PBS, was co-transfected
with the plasmid DNA. No differences were observed in editing
efficiency between cultures treated with or without rhMDM2
(Figure S3).
Genotyping Edited Clones by Sanger Sequencing
DNAwas extracted from the expanded cell clones using QuickExtract
DNA extraction solution (QE0905T, Lucigen, Middleton, WI, USA).
PCR fragments were amplified using primers 50-GGACAAGTG
CAAGAACAATGAGAACC-30 (forward) and 50-GGATGTAGC
TTTCCCAAGGTCACAGTG-30 (reverse). Deletions were undetect-
able via gel electrophoresis, so PCR products were analyzed by Sanger
sequencing. Two mutant clones with 4-bp and 10-bp out-of-frame
deletions and two wild-type clones with no detected abnormalities
were expanded. Normal karyotypes of each iPSC line were validated
with the hPSC genetic analysis kit (07550, STEMCELL Technologies,
Cambridge, MA, USA).
Differentiation of iPSCs
Confluent cultures of iPSCs were differentiated using the 14-day
direct differentiation protocol previously described.26,27 Briefly, a
given combination of Noggin, Dkk-1, insulin growth factor 1, nicotin-
amide, activin A, basic fibroblast growth factor, SU-5402, and
CHIR99021 produces directed differentiation of iPSCs into RPE
cells that exhibit key characteristics of the RPE, including pigmen-
tation, honeycomb morphology, and expression of RPE markers.
Every 30 days, cells were enzymatically digested with TryPLE Ex-
press (12604013, Thermo Fisher, Waltham, MA, USA), strained
through a 40-mm filter, and seeded at a density of 105 cells/cm2ber 2019
Figure 7. Confocal and Electron Micrographs of
iPSC-RPE Cell Monolayer after 8 Weeks on
Transwells
(A–C) Confocal fluorescent images show the basal lamina
of the RPE cells stained with antibodies for COL IV ex-
pressed at 8 weeks. A z stack was built from images
taken every 0.13 mm with a confocal microscope. 90
projections show that COL IV is expressed on the baso-
lateral membrane of the RPE cells. (D–F) Maximum in-
tensity of COL VI expressed at 8 weeks. A z stack was
built from images taken every 0.13 mm with a confocal
microscope. 90 projections show that COL VI is
deposited on the basal side of the RPE monolayer. (G–L)
Flat view by SEM at low (G–I) and high (J–L) magnification
of PRPF31+/+ and PRPF31+/ cell monolayers untreated
or treated with AAV-PRPF31 (single cells delimited by red
lines). (M–O) Section view by TEM of PRPF31+/+ and
PRPF31+/ cell monolayers untreated or treated with
AAV-PRPF31 (red lines frame gaps between cells). Scale
bars: (A)–(F), 50 mm; (G)–(I), 10 mm; (J)–(L), 1 mm; (M)–(O),
2 mm.
www.moleculartherapy.orgonto Matrigel-coated plates in X-VIVO 10 media. After 60 days in
culture, cells were seeded onto Matrigel-coated 6.5-mm polystyrene
transwells with 0.4-mm pores (3470, Corning, Bedford, MA, USA)
at a density of 20,0000 (low-density) or 200,000 (high-density) cells
per transwell. The CRISPR-edited PRPF31 mutant and wild-type
clones with better overall RPE-like morphology were chosen for the
remainder of the protocol.
qPCR
RNA from patient-derived iPSCs and CRISPR-edited iPSCs was
extracted at passage 2 using the RNeasy Mini Kit (74104,
QIAGEN, Germantown, MD, USA). Next, cDNA was synthesized
using random primers with the AffinityScript cDNA synthesis kit
(600105, Agilent) and used to assay the expression of the RPEMolecular Therapy: Methods & Clinimarkers using the TaqMan probes described
by Leach et al.27 using the Stratagene
Mx3005P qPCR system (Agilent, Santa
Clara, CA, USA). mRNA levels of PRPF31
were measured with SYBR Green using exon-
exon primers: exon 7/8 (forward, 50-AAGAT
CATGGGTGTGGCCG-30, reverse, 50-GTAG
ACGAGAAGCCCGACAG-30) and exon 11/
12 (forward, 50-TCGGAGAGATCGAGGAG
GAC-30, reverse, 50-CTGCCCGACTTGCCCA
G-30). Samples were run in triplicate using
10 ng of cDNA per well and normalized to
housekeeping genes using the delta-CTmethod.
Statistical tests were performed with GraphPad
Prism 7.
Transduction of RPE Cells
All RPE p2 cells were matured for 4 weeks
on transwells before transduction. AAV2/Anc80 AAP.CA-
SI.V5.PRPF31-mCHERRY.RBG was suspended in X-VIVO (BE04-
743Q, Lonza, Basel, Switzerland) with Normocin (ant-nr-1, Invivo-
Gen, San Diego, CA, USA) to achieve an MOI of 25,000, 50,000,
and 100,000 vector genomes (vg)/cell in a final volume of 50 mL for
low-density cultures or 100 mL for high-density cultures. AAV was
added to the iPSC-RPE cells on transwells and incubated overnight.
Media were changed the next day and twice/week afterward. All
RPE cells were cultured for 4 weeks before performing a phagocytosis
assay.
POS Phagocytosis Assay
POSs were purchased from InVision BioResources (98740, Seattle,
WA, USA) and labeled with FITC for 1 h at room temperaturecal Development Vol. 15 December 2019 399
Molecular Therapy: Methods & Clinical Development(F6434, Fisher, Waltham, MA, USA). POSs were resuspended in
enough cell media to constitute 10 POSs per cell. The patient-derived
and CRISPR-edited iPSC-RPE cells were incubated with FITC-POSs
for 30 min, 2 h, or 5 h. At the end of the incubation period, FITC-
POSs were aspirated and samples washed with PBS three times for
1 min each to stop phagocytosis. To quench FITC-POSs bound
outside of the cell, half of the samples were incubated with 0.4% try-
pan blue in PBS for 10 min at room temperature. All samples chal-
lenged with FITC-POSs were fixed with ice-cold 100% methanol
for 10 min and rehydrated with PBS. Samples without FITC-POSs
were fixed with 4% paraformaldehyde (PFA) for 10 min, followed
by 1% glutaraldehyde for 30 min, and left in PBS.
Immunocytochemistry
Transwells were cut from the chamber, cut in half with a sharp blade,
and cells were permeabilized with 0.1% Triton X-100 for 15 min, then
blocked with 0.1% BSA in PBS for 1 h.44 Primary antibodies were
diluted in 0.1% BSA in PBS and incubated with cells overnight at
4. Primary antibodies used were as follows: ZO-1 (1:100, 61-7300,
Invitrogen, Carlsbad, CA, USA), V5 (1:50, R96025, Invitrogen, Carls-
bad, CA, USA), ARL13B (1:100, 17711-1-AP, Proteintech, Rosemont,
IL, USA), COL IV (1:100, AB6586, Abcam, Cambridge, MA, USA),
and COL VI (1:100, AB6588, Abcam, Cambridge, MA, USA). Sec-
ondary antibody was diluted 1:500 in 0.1% BSA in PBS and incubated
with cells for 2 h at room temperature. Secondary antibodies used
were labeled with Alexa Fluor 488 (A11034, Thermo Fisher Scientific,
Waltham, MA, USA), Alexa Fluor 555 (A21429, Thermo Fisher Sci-
entific, Waltham, MA, USA), or Alexa Fluor 647 (A21235, Thermo
Fisher Scientific, Waltham, MA, USA). Lastly, cells were incubated
with DAPI, rinsed with PBS, and mounted with Fluoromount-G
(17984-25, Electron Microscopy Sciences, Hatfield, PA, USA).
Samples were imaged with a TCS SP5 II confocal laser scanning mi-
croscope (Leica, Allendale, NJ, USA) or fluorescence microscope
(Eclipse T, Nikon, Melville, NY, USA).
Measurement of Cilia Length
Cilia lengths were measured with ImageJ using scale bars to set the
pixel/mm ratio.
Quantification of the Fluorescent Signal
Images were converted to a binary format with ImageJ. The integrated
intensity was measured.45,46
TEM
Samples for TEM were prepared as previously described.47 Briefly,
transwells were fixed with 2.5% glutaraldehyde overnight at 4C in
0.1 M cacodylate buffer. The transwell inserts containing cell mono-
layers were cut into smaller pieces and post-fixed in 1.0% osmium te-
troxide in cacodylate buffer for 1 h at room temperature (RT), then
rinsed in cacodylate buffer. Insert pieces were then dehydrated
through a graded series of ethanol and placed pre-infiltrated over-
night with propylene oxide and Eponate 1:1. Specimens were
embedded in Eponate resin. 70-nm sections were cut using a Leica
EM UC7 ultramicrotome, collected onto Formvar-coated grids,400 Molecular Therapy: Methods & Clinical Development Vol. 15 Decemstained with uranyl acetate and Reynold’s lead citrate, and examined
in a JEOL JEM 1011 transmission electron microscope at 80 kV.
Scanning Electron Microscopy
Transwell inserts containing exposed extracellular matrix after decel-
lularization were fixed with 4% PFA for 10 min and 1% glutaralde-
hyde for 30 min at RT, followed by critical dehydration and chro-
mium coating as previously described.46,47 Samples were imaged by
a field emission scanning electron microscope (JEOL JSM 7401F).
Statistics
Results are expressed as mean ± SD, with p < 0.05 considered statis-
tically significant. Differences between groups were compared using
the Student’s t test or two-way ANOVA as appropriate using Graph-
Pad Prism software.
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